Organization
Incyte Corp.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Incyte Corp.
... to get any credit from Wall Street. That's intriguing." Others Shares of Incyte got hit hard after the conference, but the company didn't report any ...
... to expand CTP-543 into additional indications after its attempt to challenge an Incyte patent failed. The setback leaves Concert committed to taking the drug forward ...
... promoting weight loss than competitors such as Eli Lilly's Trulicity. 3. Epacadostat; Incyte: $1.6 billion This drug could be the year's most-anticipated cancer immunotherapy. Designed ...
... a major impact on the overall melanoma market. Of these pipeline agents, Incyte's IDO inhibitor epacadostat represents the sales leader with peak-year sales of $383.4M ...
... The full interview with Incyte CEO Hervé Hoppenot at J.P. Morgan Health in San Francisco. ...
... boost of around $1 billion over the two companies’ original 2015 pact. Incyte and Syros Pharmaceuticalshave penned a new target discovery, research collaboration and option ...
... Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have ...
... that it has entered into a strategic collaboration and option agreement with Incyte Corporation to identify novel targets for myeloproliferative neoplasms (MPNs), a group of ...
... Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 36th Annual J.P. ...
... Incyte Corporation (Nasdaq:INCY) today announced new 208-week (4-year) follow-up data from the ongoing, global, ...
... understand MPNs and therapies. The MPN Heroes® Recognition Event is sponsored by Incyte Corporation and CURE Media Group, publishers of CURE® magazine. Incyte partners with ...
... today announced the closing of the global collaboration and license agreement with Incyte Corporation for MGA012, an anti-PD-1 monoclonal antibody. The agreement was announced on ...
... safety and efficacy of Immunovaccine's lead immuno-oncology candidate, DPX-Survivac, in combination with Incyte's IDO1 enzyme inhibitor epacadostat, and low-dose cyclophosphamide in patients with advanced ovarian ...
... safety and efficacy of Immunovaccine's lead immuno-oncology candidate, DPX-Survivac, in combination with Incyte's IDO1 enzyme inhibitor epacadostat, and low-dose cyclophosphamide in patients with advanced ovarian ...
... acute myeloid leukemia (AML) and progress MCLA-145, being developed in collaboration with Incyte." "We are committed to unlocking the full potential of our Biclonics(R)-based bispecific ...
... acute myeloid leukemia (AML) and progress MCLA-145, being developed in collaboration with Incyte." "We are committed to unlocking the full potential of our Biclonics®-based bispecific ...
... Networks, Inc. (NYSE:CUDA), Abraxas Petroleum Corporation (NASDAQ:AXAS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Incyte Corporation (NASDAQ:INCY), Forum Energy Technologies, Inc. (NYSE:FET), and S&P Global Inc. (NYSE:SPGI) including ...
... Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the ...
... Proceedings. In October 2017, the Patent Trial and Appeal Board (PTAB) denied Incyte's petition to institute inter partes review (IPR) of U.S. Patent No. 9,249,149. ...
... cocktail can hold its own against a combination of rival drugs from Incyte and Merck. IDO1 has emerged as a key battleground in immuno-oncology as ...
... we continued to advance our clinical program in conjunction with our partners Incyte, Merck, and Dana-Farber Cancer Institute," said Frederic Ors, Immunovaccine's Chief Executive Officer. ...
Want to see the full history on Incyte Corp.? Upgrade to RelSci Pro now!
Start My Free Trial